Annovis Bio Inc (ANVS)

May 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

May 20, 2025

May 18, 2025

Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MyChesCo

May 18, 2025

May 17, 2025

Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World

May 17, 2025

May 16, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025

May 15, 2025

Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia

May 15, 2025

May 15, 2025

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

May 15, 2025

May 15, 2025

Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus

May 15, 2025

May 15, 2025

Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus

May 15, 2025

May 15, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -

May 15, 2025

May 13, 2025

Annovis Bio Appoints New Principal Financial Officer - TipRanks

May 13, 2025

May 13, 2025

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com

May 13, 2025

May 13, 2025

Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq

May 13, 2025

May 13, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025

May 13, 2025

Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan

May 13, 2025

May 10, 2025

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025

May 06, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN

May 06, 2025

Apr 30, 2025

Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -

Apr 30, 2025

Apr 29, 2025

Annovis Bio hires new director of biostatistics amid AD trial - Investing.com

Apr 29, 2025

Apr 29, 2025

Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Apr 29, 2025

Apr 26, 2025

LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025

Apr 15, 2025

Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World

Apr 15, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025

Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025

Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025

Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025

Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025

Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025